Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translational experimental models. Various characteristics of these models are examined, including the prion-like properties of -synuclein, mitochondrial functions connected to the PINK1-Parkin pathway/CHCHD2, the endolysosome pathway connected to LRRK2, VPS35, and ATP13A2 using cultured cells (including patient iPS cells). This book also highlights the future possibilities of introducing new models for Parkinson’s Disease and related movements disorders, underscoring current advancements, pre-clinical and clinical developments, and future scope related to numerous models.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Dedication - p. iii 7. Contributors - p. xv 8. Preface - p. xvii 9. Acknowledgments - p. xviii 10. Section I: Understanding PD and related movement disorders - p. xviii 11. Chapter 1. Neuroinflammation, glymphatic system, and Parkinson's disease - p. 3 12. Chapter 2. Pharmacotherapy of PD and related movements disorders and their limitations - p. 29 13. Chapter 3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders - p. 39 14. Chapter 4. OMICS and bioinformatics in Parkinson disease and related movements disorders - p. 65 15. Chapter 5. Modeling Parkinson's disease with the alpha-synuclein protein - p. 83 16. Chapter 6. α-Synuclein seeding assay and analysis - p. 97 17. Section II: Mammalian models of Parkinson's disease - p. 107 18. Chapter 7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease - p. 113 19. Chapter 8. Stem cell for PD: Technical considerations - p. 125 20. Chapter 9. Deep brain stimulation using animal models of Parkinson's disease - p. 147 21. Chapter 10. The MitoPark mouse model of Parkinson's disease - p. 167 22. Chapter 11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease - p. 187 23. Section III: Invertebrate models of Parkinson's disease - p. 197 24. Chapter 12. SCA1 zebrafish model - p. 205 25. Chapter 13. Various zebrafish models of Parkinson's disease: What gives us hope - p. 219 26. Chapter 14. Drosophila PD model - p. 231 27. Caenorhabditis elegans models of tauopathy - p. 247 28. LRRK2 in Caenorhabditis elegans model - p. 267 29. Section IV: Ethics and regulations related to translational PD models - p. 272 30. Chapter 17. Confounding factors for validation of PD models - p. 281 31. Chapter 18. Neurobehavioral characterization of PD models - p. 291 32. Chapter 19. Ethical regulations for induction and validation of PD models - p. 307 33. Chapter 20. The OMICS and PD models: Hopes or hypes - p. 321 34. Chapter 21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research - p. 345 35. Index - p. 361
Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translational experimental models. Various characteristics of these models are examined, including the prion-like properties of -synuclein, mitochondrial functions connected to the PINK1-Parkin pathway/CHCHD2, the endolysosome pathway connected to LRRK2, VPS35, and ATP13A2 using cultured cells (including patient iPS cells). This book also highlights the future possibilities of introducing new models for Parkinson’s Disease and related movements disorders, underscoring current advancements, pre-clinical and clinical developments, and future scope related to numerous models.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Dedication - p. iii 7. Contributors - p. xv 8. Preface - p. xvii 9. Acknowledgments - p. xviii 10. Section I: Understanding PD and related movement disorders - p. xviii 11. Chapter 1. Neuroinflammation, glymphatic system, and Parkinson's disease - p. 3 12. Chapter 2. Pharmacotherapy of PD and related movements disorders and their limitations - p. 29 13. Chapter 3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders - p. 39 14. Chapter 4. OMICS and bioinformatics in Parkinson disease and related movements disorders - p. 65 15. Chapter 5. Modeling Parkinson's disease with the alpha-synuclein protein - p. 83 16. Chapter 6. α-Synuclein seeding assay and analysis - p. 97 17. Section II: Mammalian models of Parkinson's disease - p. 107 18. Chapter 7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease - p. 113 19. Chapter 8. Stem cell for PD: Technical considerations - p. 125 20. Chapter 9. Deep brain stimulation using animal models of Parkinson's disease - p. 147 21. Chapter 10. The MitoPark mouse model of Parkinson's disease - p. 167 22. Chapter 11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease - p. 187 23. Section III: Invertebrate models of Parkinson's disease - p. 197 24. Chapter 12. SCA1 zebrafish model - p. 205 25. Chapter 13. Various zebrafish models of Parkinson's disease: What gives us hope - p. 219 26. Chapter 14. Drosophila PD model - p. 231 27. Caenorhabditis elegans models of tauopathy - p. 247 28. LRRK2 in Caenorhabditis elegans model - p. 267 29. Section IV: Ethics and regulations related to translational PD models - p. 272 30. Chapter 17. Confounding factors for validation of PD models - p. 281 31. Chapter 18. Neurobehavioral characterization of PD models - p. 291 32. Chapter 19. Ethical regulations for induction and validation of PD models - p. 307 33. Chapter 20. The OMICS and PD models: Hopes or hypes - p. 321 34. Chapter 21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research - p. 345 35. Index - p. 361
